JMCP’s Call to Action in Addressing Racial Disparities in Medication Use
In a recently published article, the editorial team at 'Journal of Managed Care + Specialty Pharmacy' (JMCP) raised the question [...]
Takeda Partners With Seqster on Patient-centric Data
Seqster, a San Diego-based health technology firm, developed a platform to securely collate and store patient data such as electronic [...]
Milestones in managed care pharmacy
There have been major achievements in managed care pharmacy’s short 50-year history. Significant milestones include establishment of the pharmacy benefit [...]
FDA and Industry Set Priorities Through Prescription Drug User Fee Act (PDUFA) Reauthorization
The FDA first began the Prescription Drug User Fee Act (PDUFA) reauthorization process in July. Now the agency has released [...]
FDA Decision Alerts for AYVAKIT™ (avapritinib) and IBRANCE (palbociclib)
Blueprint Medicines Corporation’s AYVAKIT (avapritinib) was approved for adult patients with a specific type of unresectable or metastatic gastrointestinal stromal [...]
Generating Insights from RWD: Opportunities for Small and Mid-sized Biopharma
Optum possesses a robust range of real-world data (RWD) assets that afford small and mid-sized biopharma the unique opportunity to [...]
[Podcast] Where Value-Based Payments and Behavioral Health Intersect
Tune in to this healthcare podcast featuring Don Fowls, MD, president of Don Fowls and Associates, and past president of [...]
[White Paper] Integrated Scientific Advice and Multiple Stakeholder Engagements
Ensuring the best chance of success for new technologies through development of evidence generation plans requires multi-stakeholder involvement with patients, [...]
NICE Talking to You: The Value of Early Scientific Advice
Starting in 2009, NICE became a pioneer among health technology assessment (HTA) agencies by offering the opportunity for early scientific [...]
The Disturbing Dearth of Evidence for Supportive Oncology
Despite historical reliance on evidence generated from randomized controlled trials (RCTs), there has been a surge in the number of [...]
ICER Launches New Podcast: A Prescription for Fair Drug Pricing
America’s got a fever. And the only prescription? More cowbell—and fair drug pricing. To that end, ICER announced the launch [...]
[White Paper] Health Technology Assessment During the COVID-19 Pandemic
The global COVID-19 pandemic currently permeates every aspect of daily life with long-lasting consequences for all sectors, including pharma and [...]
COVID-19 Vaccine Will Come At No Cost to Medicare Beneficiaries
Once approved, the Trump administration will cover COVID-19 vaccinations at no cost to Medicare beneficiaries. On Wednesday, CMS released an [...]
Evidence Forum Announces Fall Issue
Evidera’s biannual publication, Evidence Forum, explores the pressing scientific, strategic, and operational challenges of the current healthcare environment. The fall [...]
New Rule Requires Payers To Post Negotiated Rates, Cost-sharing Data
The Trump administration announced today that it has finalized a rule requiring private insurers to provide members with upfront prices negotiated [...]
AMI’s Specialty Pharmacy Database Enjoys Growing Accreditation Status
AMI’s Specialty Pharmacy Database recently gained accreditation status from four agencies: URAC, Accreditation Commission for Health Care (ACHC), The Center [...]
Bureaucrats May Stop Life-saving Meds from Reaching Canada
If Canadian bureaucrats on the Patent Medicine Prices Review Board (PMPRB) get their way, innovative new drugs and vaccines may not come [...]
How Can Payers Advance Patient-reported Measures in Oncology?
A newly published study explored patient-reported performance measures in oncology, the barriers to implementation, and actionable recommendations for public and [...]
Achieving Accurate Estimates of Shared Savings from Value-based Healthcare
This article is part of a series focused on calculating shared savings from value-based health care improvement solutions. There is [...]
[Podcast] Bruno Villetelle on Real World Data’s Role in Bringing Medication to Market
In this episode of Real World Talk, join host Emily Di Capua as she discusses the ways in which RWD [...]
[Virtual Summit] How much drug research will we sacrifice to save money?
Tune in to the 2020 STAT Summit On November 18th at 3:45pm ET for a robust discussion on the cost [...]
[Webinar] Putting Artificial Intelligence in R&D
Big Pharma and biotech are increasingly using artificial intelligence in drug discovery. Join a distinguished panel of experts on October [...]
ISPOR Invites Applications For President-Elect or Director
The ISPOR Nominations Committee is now inviting members to nominate themselves or a colleague or to serve as President-Elect or [...]
Value-based Care at Risk
An April survey by the National Association of ACOs showed that more than half the organizations in at-risk models planned [...]
Payers: The New Catalysts of Better Health
As health care delivery is getting more complex, the traditional definition of healthcare is evolving. This shift is necessitating the [...]